Gemcitabine Combined With Mistletoe in Treating Patients With Advanced Solid Tumors

DISEASE CHARACTERISTICS: Histologically confirmed metastatic, recurrent, or unresectable locally advanced solid tumor, including one of the following: Breast or colorectal cancer that has failed first-line chemotherapy Non-small cell lung cancer Pancreatic Cancer No CNS metastases Hormone receptor status: Not specified PATIENT CHARACTERISTICS: Age 18 and over Sex Male or female Menopausal status Not specified Performance status ECOG 0-1 Life expectancy Not specified Hematopoietic Absolute neutrophil count at least 1,500/mm^3 Platelet count at least 100,000/mm^3 Hepatic Bilirubin no greater than 2.0 mg/dL No clinically significant hepatic dysfunction Renal Creatinine no greater than 2.5 mg/dL No clinically significant renal dysfunction Other Not pregnant or nursing Negative pregnancy test HIV negative No clinically significant unrelated illness (e.g., serious infection or organ dysfunction) that would preclude study tolerance PRIOR CONCURRENT THERAPY: Biologic therapy No prior mistletoe Chemotherapy See Disease Characteristics No prior gemcitabine More than 30 days since prior chemotherapy and recovered Endocrine therapy More than 30 days since prior glucocorticosteroid therapy Radiotherapy Recovered from prior radiotherapy Surgery Recovered from prior surgery Other At least 30 days since prior investigational agents No other concurrent investigational agents